Morbidity of transrectal ultrasonography-guided prostate biopsies in patients after the continued use of low-dose aspirin
Article first published online: 23 MAY 2003
Volume 91, Issue 9, pages 798–800, June 2003
How to Cite
Maan, Z., Cutting, C.W., Patel, U., Kerry, S., Pietrzak, P., Perry, M.J.A. and Kirby, R.S. (2003), Morbidity of transrectal ultrasonography-guided prostate biopsies in patients after the continued use of low-dose aspirin. BJU International, 91: 798–800. doi: 10.1046/j.1464-410X.2003.04238.x
- Issue published online: 23 MAY 2003
- Article first published online: 23 MAY 2003
- Accepted for publication 7 February 2003
To determine whether low-dose aspirin increases morbidity after transrectal ultrasonography-guided sextant prostate biopsy.
PATIENTS AND METHODS
In a single-centre prospective cohort study of 200 patients who underwent sextant prostate biopsies, those routinely taking low-dose aspirin were encouraged to continue to do so before and after biopsy. The morbidity in each case was assessed using a standardized questionnaire that patients completed in the 7 days after biopsy. The presence of haematuria, rectal bleeding and haematospermia were recorded. The questionnaire also directed the patient to record fevers, use of analgesia and any further treatment received.
In all, 36 patients took aspirin whilst the other 141 did not. There were no major complications in either group. Of the patients on aspirin, 20 (56%) had haematuria, compared with 83 (59%) of those not taking aspirin (difference 3%, 95% confidence interval, CI, −15 to 21). Overall bleeding (haematuria, rectal bleeding and haematospermia) occurred in 22 patients (61%) of the aspirin group and 105 (74%) of the other group (difference 13%, 95% CI −4 to 31). Comparisons of other morbidities between the groups are also discussed.
There was no statistically significant difference in the incidence of haematuria or overall bleeding after biopsy between the groups. There is no evidence that aspirin needs to be discontinued before sextant prostate biopsy.